Physician profile
Christopher P Bunce
NPI 1053350405
$2,225.45
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $68.42 · 2021: $31.90 · 2022: $61.47 · 2023: $848 · 2024: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925 · Grant: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.25 |
| Grant | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $607.14 | 2023-2024 | Dalvance |
| Insmed, INC. | $177.46 | 2019-2024 | Arikayce |
| Jazz Pharmaceuticals INC. | $175.94 | 2023-2024 | |
| Viiv Healthcare Company | $126.34 | 2019-2024 | Dovato |
| Merck Sharp & Dohme LLC | $125.60 | 2019-2024 | Verquvo, Gardasil 9, Gardasil |
| Novo Nordisk INC | $118.92 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Genentech USA, INC. | $118.13 | 2019 | |
| Pfizer INC. | $82.54 | 2019-2020 | |
| Lilly USA, LLC | $51.70 | 2022-2023 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $49.69 | 2019-2024 | Farxiga |
| Axsome Therapeutics, INC. | $40.31 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2021-2023 | Tradjenta |
| La Jolla Pharmaceutical Company | $37.53 | 2023 | Xerava |
| Astellas Pharma US INC | $36.88 | 2019 | |
| Glaxosmithkline, LLC. | $34.22 | 2023 | Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $33.41 | 2019 | |
| Fortovia Therapeutics, INC. | $31.86 | 2019 | |
| Inspire Medical Systems, INC. | $31.86 | 2023 | Inspire |
| Tetraphase Pharmaceuticals, INC. | $31.13 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.55 | 2019-2024 | |
| Gilead Sciences, INC. | $29.11 | 2019-2021 | |
| Resmed Corp | $28.61 | 2023-2024 | |
| Partner Therapeutics, INC. | $24.16 | 2019 | |
| Allergan, INC. | $22.65 | 2019 | |
| Melinta Therapeutics, LLC | $20.80 | 2019 | |
| Eisai INC. | $19.71 | 2020 | |
| Theratechnologies INC. | $17.20 | 2019 | |
| Mayne Pharma Commercial LLC | $17.04 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.29 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $14.77 | 2023 | Rexulti |
| Exact Sciences Corporation | $13.59 | 2024 | Cologuard Collection Kit |
| Tactile Systems Technology INC | $11.46 | 2019 | |
| Napo Pharmaceuticals INC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bunce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.